Key Points
- COO Michael Benkowitz sold 22,500 shares on Dec. 15 at an average price of $496.30 for $11,166,750, the latest in a string of weekly sales (11 total sales of 22,500 shares each) since Oct. 6 — totaling 247,500 shares sold for roughly $112.9 million.
- United Therapeutics shares are trading near a one-year high around $500 with a market cap of about $21.5 billion; analysts have a consensus "Moderate Buy" and an average price target of $505, while the company recently reported quarterly EPS of $7.16, beating estimates.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Christopher Patusky sold 1,000 shares of the firm's stock in a transaction on Monday, December 15th. The stock was sold at an average price of $495.95, for a total value of $495,950.00. Following the completion of the transaction, the director owned 1,490 shares in the company, valued at $738,965.50. This represents a 40.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
United Therapeutics Trading Down 0.1%
United Therapeutics stock opened at $500.00 on Wednesday. The firm has a market capitalization of $21.53 billion, a P/E ratio of 18.95, a PEG ratio of 4.97 and a beta of 0.86. The business has a 50-day moving average of $459.61 and a 200-day moving average of $377.40. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $502.77.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period last year, the business posted $6.39 earnings per share. The business's revenue for the quarter was up 6.8% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Hedge Funds Weigh In On United Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Allworth Financial LP raised its position in United Therapeutics by 26.1% during the third quarter. Allworth Financial LP now owns 449 shares of the biotechnology company's stock worth $188,000 after acquiring an additional 93 shares in the last quarter. Cambria Investment Management L.P. increased its stake in shares of United Therapeutics by 20.9% during the 3rd quarter. Cambria Investment Management L.P. now owns 2,657 shares of the biotechnology company's stock worth $1,114,000 after purchasing an additional 460 shares during the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of United Therapeutics by 66.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 713 shares of the biotechnology company's stock worth $299,000 after purchasing an additional 284 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $644,000. Finally, Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. 94.08% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on UTHR. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an "equal weight" rating in a research note on Thursday, October 30th. Bank of America upped their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. UBS Group boosted their price target on United Therapeutics from $580.00 to $600.00 and gave the company a "buy" rating in a report on Thursday, November 6th. HC Wainwright increased their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a "buy" rating in a report on Thursday, October 30th. Finally, Cantor Fitzgerald lifted their target price on United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $505.00.
View Our Latest Analysis on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
